CompletedPhase 2NCT01457781
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bellerophon Pulse Technologies
- Principal Investigator
- Ashika Ahmed, MDBellerophon Therapeutics
- Intervention
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device(combination_product)
- Enrollment
- 80 enrolled
- Eligibility
- 16-80 years · All sexes
- Timeline
- 2012 – 2016
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- Allianz Research Institute, Inc., Fountain Valley, California, United States
- University of California, San Francisco-Fresno, Fresno, California, United States
- West Los Angeles VA Healthcare Center, Los Angeles, California, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- Los Angeles Biomedical Research Institute at Harbor-UCLA Med Ctr, Torrance, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- University of Colorado Denver, Aurora, Colorado, United States
- South Denver Cardiology Associates P.C., Littleton, Colorado, United States
- Christiana Care Health System, Newark, Delaware, United States
- University of Florida College of Medicine, Jacksonville, Florida, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- Emory University Hospital-Emory Clinic, Atlanta, Georgia, United States
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01457781 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →